Insider Transactions in Q1 2023 at Eye Point Pharmaceuticals, Inc. (EYPT)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2023
|
Goran Ando |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+28.51%
|
-
|
|
Feb 09
2023
|
John B. Landis |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+20.83%
|
-
|
|
Feb 09
2023
|
Wendy F Dicicco |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+28.85%
|
-
|
|
Feb 09
2023
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,744
-6.57%
|
$14,976
$4.17 P/Share
|
|
Feb 09
2023
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+16.95%
|
-
|
|
Feb 09
2023
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+28.85%
|
-
|
|
Feb 09
2023
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,956
-5.41%
|
$11,824
$4.17 P/Share
|
|
Feb 09
2023
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,967
+16.41%
|
-
|
|
Feb 09
2023
|
Jay S. Duker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,148
-6.42%
|
$16,592
$4.17 P/Share
|
|
Feb 09
2023
|
Jay S. Duker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,967
+16.36%
|
-
|
|
Feb 09
2023
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
37,533
+9.41%
|
-
|
|
Feb 09
2023
|
George Elston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+21.0%
|
-
|